Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 720 DKK -1.1%
Market Cap: 50.9B DKK
Have any thoughts about
Zealand Pharma A/S?
Write Note

Zealand Pharma A/S
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Zealand Pharma A/S
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Zealand Pharma A/S
CSE:ZEAL
Long-Term Debt
kr373.6m
CAGR 3-Years
43%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genmab A/S
CSE:GMAB
Long-Term Debt
kr925m
CAGR 3-Years
34%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Ascendis Pharma A/S
NASDAQ:ASND
Long-Term Debt
€338.9m
CAGR 3-Years
52%
CAGR 5-Years
61%
CAGR 10-Years
N/A
B
Bavarian Nordic A/S
CSE:BAVA
Long-Term Debt
kr82.7m
CAGR 3-Years
-67%
CAGR 5-Years
-29%
CAGR 10-Years
2%
Bioporto A/S
CSE:BIOPOR
Long-Term Debt
kr3.5m
CAGR 3-Years
-23%
CAGR 5-Years
24%
CAGR 10-Years
43%
Saniona AB
STO:SANION
Long-Term Debt
kr40.3m
CAGR 3-Years
47%
CAGR 5-Years
69%
CAGR 10-Years
N/A
No Stocks Found

Zealand Pharma A/S
Glance View

Market Cap
50.9B DKK
Industry
Biotechnology

Zealand Pharma A/S is a Danish biotechnology company that has carved a niche in the medical field by focusing on the design and development of innovative peptide-based medicines. Established in 1998 and headquartered in Copenhagen, the company is driven by a singular mission: to improve patients' lives through impactful treatments. Zealand's expertise lies in peptide therapeutics, a compelling segment of biopharmaceuticals due to their ability to mimic biological processes with high specificity and efficacy. The company has a keen focus on addressing unmet medical needs, particularly in the treatment of metabolic and gastrointestinal diseases. With a robust pipeline that ranges from early-stage research to late-stage clinical trials, Zealand Pharma leverages its proprietary technology to discover and develop novel pharmaceuticals that can be game-changers in their respective therapeutic areas. Zealand Pharma's business model centers around the development and commercialization of its proprietary medicines, both independently and through strategic partnerships. By collaborating with larger pharmaceutical companies, Zealand enhances its global commercialization capabilities and mitigates the financial risks inherent in drug development. For instance, the company has partnered with multinational corporations, allowing it to tap into resources for advanced research, regulatory processes, and worldwide distribution systems. Revenue streams are diversified through milestone payments, royalties, and direct sales, ensuring a steady inflow of cash that supports continued innovation. This strategic approach not only sustains its operations but also propels its mission of delivering transformative healthcare solutions. In essence, Zealand Pharma thrives at the confluence of science and strategy, driving both its financial health and its contributions to the biopharmaceutical landscape.

ZEAL Intrinsic Value
201.52 DKK
Overvaluation 72%
Intrinsic Value
Price

See Also

What is Zealand Pharma A/S's Long-Term Debt?
Long-Term Debt
373.6m DKK

Based on the financial report for Sep 30, 2024, Zealand Pharma A/S's Long-Term Debt amounts to 373.6m DKK.

What is Zealand Pharma A/S's Long-Term Debt growth rate?
Long-Term Debt CAGR 3Y
43%

Over the last year, the Long-Term Debt growth was 270%. The average annual Long-Term Debt growth rates for Zealand Pharma A/S have been 43% over the past three years .

Back to Top